| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |